BAVARIAN NORDIC A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 148.8 DKK | +3.26% |
|
+1.02% | -16.12% |
| 03-13 | Swiss Regulator Clears Bavarian Nordic’s Jynneos for Smallpox Immunization in Adults | MT |
| 03-13 | Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland | CI |
| Sales 2024 * | 5.22B 748M 59.87B | Sales 2025 * | 5.06B 725M 58.03B | Capitalization | 11.6B 1.66B 133B |
|---|---|---|---|---|---|
| Net income 2024 * | 630M 90.35M 7.23B | Net income 2025 * | 855M 123M 9.81B | EV / Sales 2024 * | 2.11 x |
| Net cash position 2024 * | 569M 81.66M 6.53B | Net cash position 2025 * | 861M 123M 9.88B | EV / Sales 2025 * | 2.12 x |
| P/E ratio 2024 * |
18.3
x | P/E ratio 2025 * |
13.6
x | Employees | 1,379 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.85% |
More Fundamentals
* Assessed data
More news
Latest transcript on Bavarian Nordic A/S
More press releases
More news
| 1 day | +3.26% | ||
| 1 week | +1.02% | ||
| Current month | -3.94% | ||
| 1 month | -4.03% | ||
| 3 months | -4.49% | ||
| 6 months | +14.68% | ||
| Current year | -16.12% |
1 week
143.75
152.95
1 month
143.40166.05
Current year
143.40182.50
1 year
125.55222.00
3 years
115.20411.00
5 years
103.20411.00
10 years
100.00444.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Chaplin
CEO | Chief Executive Officer | 57 | 31/12/98 |
Henrik Juuel
DFI | Director of Finance/CFO | 59 | 31/10/18 |
Russell Thirsk
COO | Chief Operating Officer | 56 | 31/03/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 73 | 26/04/10 | |
| Director/Board Member | 57 | 31/12/22 | |
Frank Verwiel
BRD | Director/Board Member | 62 | 19/04/16 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.02% | 773 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 148.8 | +3.26% | 291,607 |
| 25/04/24 | 144.2 | -3.58% | 438,710 |
| 24/04/24 | 149.5 | -1.06% | 264,387 |
| 23/04/24 | 151.1 | +0.67% | 339,056 |
| 22/04/24 | 150.1 | +1.87% | 421,064 |
Delayed Quote Nasdaq Copenhagen, April 26, 2024 at 03:59 pm
More quotes
Bavarian Nordic A/S specializes in the development, manufacturing and commercialization of cancer immunotherapies and vaccines for the prevention and treatment of infectious diseases.
Net sales by revenue source are divided between sales of products (97.8%) and services (2.2%).
Net sales are distributed geographically as follows: the United States (36.5%), Canada (22%), France (10.5%), Germany (10.1%), Spain (6.1%), Australia (4.8%), Switzerland ( 1.5%), Sweden (1%), Chile (0.9%), Taiwan (0.8%), the United Kingdom (0.6%), Hong Kong (0.2%), Saudi Arabia (0.1%), and others (4.9%).
Sector
Pharmaceuticals
Calendar
07/05/2024
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
148.8
DKK
Average target price
264.8
DKK
Spread / Average Target
+77.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.12% | 1.66B | |
| +25.83% | 661B | |
| +27.00% | 566B | |
| -6.76% | 352B | |
| +20.34% | 332B | |
| +3.00% | 283B | |
| +13.09% | 231B | |
| +5.46% | 200B | |
| -9.61% | 195B | |
| -6.26% | 145B |
- Stock Market
- Equities
- BAVA Stock
